MedTrace Logo

Study on Skin Microbiome of HFS

NCT04132713 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-10-21

No results posted yet for this study

Summary

To skin microecology and breast cancer chemotherapy drug therapy as the breakthrough point, disease prevention and treatment of breast cancer in China, the important scientific problems in basic research, through in-depth study of skin micro ecological changes in advanced breast cancer chemotherapy and its regulatory mechanism, clear skin flora occurred after application of capecitabine and the influence and mechanism of the immune response;Finding markers for the treatment and prognosis of related diseases;Identify and isolate key strains and/or metabolites, and conduct intervention studies to reveal new mechanisms of skin microflora homeostasis and toxic and side effects of breast cancer chemotherapy.

Conditions

  • Microbiota

Interventions

DRUG

Capecitabine 150Mg Oral Tablet

Advanced breast cancer patients with first-line medication

Sponsors & Collaborators

  • Sponsor GmbH

    collaborator OTHER

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2020-10-15
Completion
2020-10-15
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04132713 on ClinicalTrials.gov